Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 121

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 121
---
 the registration requirements in Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.

<div align='center'>69</div>

PLAN OF DISTRIBUTION Pursuant to an engagement letter dated as of January 23, 2025, we have engaged Dawson James to act as our exclusive placement agent to solicit offers to purchase the Units offered by this prospectus on a best efforts basis. The engagement letter does not give rise to any commitment by Dawson James to purchase any of our securities, and Dawson James will have no authority to bind us by virtue of the engagement letter. Dawson James is not purchasing or selling any such securities, nor is it required to arrange for the purchase and sale of any specific number or dollar amount of such securities, other than to use its “best efforts” to arrange for the sale of such securities by us. Therefore, we may not sell all, or any, of the Units being offered. The terms of this offering were subject to market conditions and negotiations between us, Dawson James and prospective investors. This is a best efforts offering and there is no minimum number of securities or minimum aggregate amount of proceeds that is a condition to the closing of this offering. Dawson James may retain sub-agents and selected dealers in connection with this offering. We will have one closing for all the securities purchased in this offering. The public offering price per Unit will be fixed for the duration of this offering. Delivery of the securities offered hereby is expected to occur on or about , 2025, subject to satisfaction of certain customary closing conditions. We have agreed to pay Dawson James an aggregate cash fee equal to 8% of the gross proceeds received in the offering. In addition, we have agreed to reimburse Dawson James for their legal fees, costs and expenses in connection with this offering in an amount up to $125,000. We estimate the total expenses of this offering paid or payable by us, exclusive of Dawson James’ cash fees and expenses, will be approximately $1.9 million. After deducting the fees due to Dawson James and our estimated expenses in connection with this offering, we expect the net proceeds from this offering will be approximately $18.1 million based on an assumed public offering price of $0.269, which was the last reported sales price of our common stock on The Nasdaq Capital Market on February 6, 2025. The following table shows the per share and total cash fees we will pay to Dawson James in connection with the sale of the securities pursuant to this prospectus.